Dados B3 › OPTS3 × OIBR3
OPTS3 × OIBR3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | OPTS3 | OIBR3 | year |
|---|---|---|---|
| ROE | -5.9% | -243.5% | 2021 |
| ROIC | -2.0% | -91.3%! | 2022 |
| ROA | -1.3% | -212.9% | 2025 |
| Gross margin | 57.0% | 4.5% | 2023 |
| EBIT margin | 11.6% | -18.6% | 2023 |
| Net margin | — | -1,399.8% | no year where both have it |
| Net debt/EBITDA | — | 15.21x | no year where both have it |
| Current ratio | 0.02x | 1.12x | 2025 |
| Revenue growth (1y) | -47.2% | -7.3% | 2023 |
| Revenue growth (5y CAGR) | — | -25.0% | no year where both have it |
| Piotroski F-Score | 2/9! | 4/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | OPTS3 | OIBR3 | year |
|---|---|---|---|
| P/E | — | 0.00x | None × 2024 |
| P/B | — | — | None × 2024 |
| EV/EBITDA | — | — | None × 2024 |
| FCF yield | — | -352,559.1% | None × 2024 |
compare up to 4 assets, with 1- and 5-year returns
Numbers on this page are live. Data version 2026-11-09-ancora-do-fre · page generated 2026-11-22 22:21 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-11-09-ancora-do-fre · page generated 2026-11-22 22:21 UTC. If this does not match /saude, you are reading a cached copy.